Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 4/2021

01.04.2021 | Autoimmunity (TK Tarrant, Section Editor)

Fatal Anaphylaxis: Epidemiology and Risk Factors

verfasst von: Irene Mikhail, David R. Stukus, Benjamin T. Prince

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To provide clinicians with an understanding of risk factors associated with fatal anaphylaxis, and to promote individualized management plans with patients based upon key aspects of their clinical history.

Recent Findings

While anaphylaxis can affect a significant percentage of the general population, death from anaphylaxis remains a rare outcome. The presence of asthma and peanut or tree nut allergy is associated with higher risk for severe or fatal anaphylaxis from foods. Specific triggers (medications, venom), underlying comorbid conditions, age, and use of some medications can also impact risk and warrant different counseling and management strategies.

Summary

Anaphylaxis is a rapidly progressive systemic reaction with multiple different causes and encompasses a wide degree of severity in clinical presentation and risk for future episodes. Individualized management, discussion of risk, and shared decision making should occur with each patient and in consideration of their personal risk factors.
Literatur
1.
•• Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391–7 A comprehensive review of anaphylaxis diagnostic criteria and practical application in the clinical setting.PubMedCrossRef
2.
Simons FE, Ardusso LR, Bilò MB, Cardona V, Ebisawa M, El-Gamal YM, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014;7(1):9.PubMedPubMedCentralCrossRef
3.
Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, et al. Anaphylaxis: clinical patterns, mediator release, and severity. J Allergy Clin Immunol. 2013;132(5):1141–1149.e5.PubMedCrossRef
4.
Santos AF, Shreffler WG. Road map for the clinical application of the basophil activation test in food allergy. Clin Exp Allergy. 2017;47(9):1115–24.PubMedPubMedCentralCrossRef
5.
Wood RA, Camargo CA Jr, Lieberman P, Sampson HA, Schwartz LB, Zitt M, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461–7.PubMedCrossRef
6.
Pouessel G, Turner PJ, Worm M, Cardona V, Deschildre A, Beaudouin E, et al. Food-induced fatal anaphylaxis: from epidemiological data to general prevention strategies. Clin Exp Allergy. 2018;48(12):1584–93.PubMedCrossRef
7.
Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol. 2015;135(4):956–63.e1.PubMedPubMedCentralCrossRef
8.
Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014;134(6):1318–1328.e7.PubMedPubMedCentralCrossRef
9.
Dorris S. Fatal food anaphylaxis: registering a rare outcome. Ann Allergy Asthma Immunol. 2020;124(5):445–6.PubMedCrossRef
10.
Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis: mortality rate and risk factors. J Allergy Clin Immunol Pract. 2017;5(5):1169–78.PubMedPubMedCentralCrossRef
11.
Michelson KA, Dribin TE, Vyles D, Neuman MI. Trends in emergency care for anaphylaxis. J Allergy Clin Immunol Pract. 2020;8(2):767–768.e2.PubMedCrossRef
12.
Grabenhenrich LB, Dölle S, Moneret-Vautrin A, Köhli A, Lange L, Spindler T, et al. Anaphylaxis in children and adolescents: the European Anaphylaxis Registry. J Allergy Clin Immunol. 2016;137(4):1128–1137.e1.PubMedCrossRef
13.
Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona V, et al. First European data from the network of severe allergic reactions (NORA). Allergy. 2014;69(10):1397–404.PubMedCrossRef
14.
Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009;123(2):434–42.PubMedCrossRef
15.
Golden DBK. Anaphylaxis: recognizing risk and targeting treatment. J Allergy Clin Immunol Pract. 2017 Sep-Oct;5(5):1224–6.PubMedCrossRef
16.
Stukus DR. Early Recognition of anaphylaxis in high risk settings. In: Ellis A, editor. Anaphylaxis – a practical guide. New York: Springer Science+Business Media; 2019.
17.
Mullins RJ, Wainstein BK, Barnes EH, Liew WK, Campbell DE. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy. 2016;46(8):1099–110.PubMedCrossRef
18.
Reitter M, Petitpain N, Latarche C, Cottin J, Massy N, Demoly P. et al; French Network of Regional Pharmacovigilance Centres. Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis. Allergy. 2014;69(7):954–9.PubMedCrossRef
19.
Gülen T, Ljung C, Nilsson G, Akin C. Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis. J Allergy Clin Immunol Pract. 2017;5(5):1248–55.PubMedCrossRef
20.
Lee S, Hess EP, Nestler DM, Bellamkonda Athmaram VR, Bellolio MF, Decker WW, et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol. 2013;131(4):1103–8.PubMedCrossRef
21.
Greenberger PA. Fatal and near-fatal anaphylaxis: factors that can worsen or contribute to fatal outcomes. Immunol Allergy Clin N Am. 2015;35(2):375–86.CrossRef
22.
Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327(6):380–4.PubMedCrossRef
23.
Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(4):1075–83.PubMedCrossRef
24.
Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S. Anaphylaxis-related deaths in Ontario: a retrospective review of cases from 1986 to 2011. Allergy, Asthma Clin Immunol. 2014;10(1):38.CrossRef
25.
Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107(1):191–3.PubMedCrossRef
26.
Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol. 2007;119(4):1016–8.PubMedCrossRef
27.
Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol. 2007;119(4):1018–9.PubMedCrossRef
28.
Pouessel G, Claverie C, Labreuche J, Dorkenoo A, Renaudin JM, Eb M, et al. Fatal anaphylaxis in France: analysis of national anaphylaxis data, 1979-2011. J Allergy Clin Immunol. 2017;140(2):610–612.e2.PubMedCrossRef
29.
Turner PJ, Baumert JL, Beyer K, Boyle RJ, Chan CH, Clark AT, et al. Can we identify patients at risk of life-threatening allergic reactions to food? Allergy. 2016;71(9):1241–55.PubMedCrossRef
30.
Umasunthar T, Leonardi-Bee J, Hodes M, Turner PJ, Gore C, Habibi P, et al. Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2013;43(12):1333–41.PubMedPubMedCentralCrossRef
31.
Grabenhenrich LB, Dölle S, Ruëff F, Renaudin JM, Scherer K, Pföhler C, et al. Epinephrine in severe allergic reactions: the european anaphylaxis register. J Allergy Clin Immunol Pract. 2018;6(6):1898–1906.e1.PubMedCrossRef
32.
Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy. 2000;30(8):1144–50.PubMedCrossRef
33.
Shaker MS, Schwartz J, Ferguson M. An update on the impact of food allergy on anxiety and quality of life. Curr Opin Pediatr. 2017;29(4):497–502.PubMedCrossRef
34.
Bilo MB, Corsi A, Martini M, Penza E, Grippo F, Bignardi D. Fatal anaphylaxis in Italy: analysis of cause-of-death national data, 2004-2016. Allergy. 2020.
35.
•• Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259-73. Thorough reference for the presentation, evaluation, and management of various forms of drug hypersensitivity reactions.
36.
Kuruvilla M, Khan DA. Anaphylaxis to drugs. Immunol Allergy Clin N Am. 2015;35(2):303–19.CrossRef
37.
Saff RR. Immediate local anesthetic reactions: too quick to point the finger? J Allergy Clin Immunol Pract. 2018;6(4):1224–5.PubMedCrossRef
38.
Motosue MS, Bellolio MF, Van Houten HK, Shah ND, Campbell RL. Risk factors for severe anaphylaxis in the United States. Ann Allergy Asthma Immunol. 2017;119(4):356–61 e2.PubMedCrossRef
39.
Hsu Blatman KS, Hepner DL. Current knowledge and management of hypersensitivity to perioperative drugs and radiocontrast media. J Allergy Clin Immunol Pract. 2017;5(3):587–92.PubMedCrossRef
40.
Volcheck GW, Hepner DL. Identification and management of perioperative anaphylaxis. J Allergy Clin Immunol Pract. 2019;7(7):2134–42.PubMedCrossRef
41.
•• Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28–54 The go-to source for comprehensive information regarding venom allergy, including presentation, evaluation, risk factors, and treatment.PubMedCrossRef
42.
Golden DB. Anaphylaxis to insect stings. Immunol Allergy Clin N Am. 2015;35(2):287–302.CrossRef
43.
Stoevesandt J, Sturm GJ, Bonadonna P, Oude Elberink JNG, Trautmann A. Risk factors and indicators of severe systemic insect sting reactions. Allergy. 2020;75(3):535–45.PubMedCrossRef
44.
Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124(5):1047–54.PubMedCrossRef
45.
Worm M, Francuzik W, Renaudin JM, Bilo MB, Cardona V, Scherer Hofmeier K, et al. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry. Allergy. 2018;73(6):1322–30.PubMedCrossRef
46.
Chapsa M, Roensch H, Langner M, Beissert S, Bauer A. Predictors of severe anaphylaxis in Hymenoptera venom allergy: the importance of absence of urticaria and angioedema. Ann Allergy Asthma Immunol. 2020;125(1):72–7.PubMedCrossRef
47.
Bonadonna P, Scaffidi L. Hymenoptera anaphylaxis as a clonal mast cell disorder. Immunol Allergy Clin N Am. 2018;38(3):455–68.CrossRef
48.
Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015;136(1):135–9.PubMedCrossRef
49.
Vos B, van Anrooij B, van Doormaal JJ, Dubois AEJ, Oude Elberink JNG. Fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of at-risk patients. J Allergy Clin Immunol Pract. 2017;5(5):1264–71.PubMedCrossRef
50.
Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E, et al. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract. 2018;6(4):1368–72.PubMedCrossRef
51.
•• McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463–72 Thorough review of adverse reactions to vaccines, particularly the causes and presentation of hypersensitivity reactions.PubMedPubMedCentralCrossRef
52.
Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the vaccine adverse event reporting system, 1990-2016. J Allergy Clin Immunol. 2019;143(4):1465–73.PubMedPubMedCentralCrossRef
53.
Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815–20.PubMedCrossRef
54.
McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868–78.PubMedCrossRef
55.
Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics. 2002;110(6):e71.PubMedCrossRef
56.
Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25–43.PubMedCrossRef
57.
Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: a practice parameter update 2017. Ann Allergy Asthma Immunol. 2018;120(1):49–52.PubMedCrossRef
58.
Geller M. Clinical management of exercise-induced anaphylaxis and cholinergic urticaria. J Allergy Clin Immunol Pract. 2020;8(7):2209–14.PubMedCrossRef
59.
Feldweg AM. Exercise-induced anaphylaxis. Immunol Allergy Clin N Am. 2015;35(2):261–75.CrossRef
60.
Yee CSK, El Khoury K, Albuhairi S, Broyles A, Schneider L, Rachid R. Acquired cold-induced urticaria in pediatric patients: a 22-year experience in a tertiary care center (1996-2017). J Allergy Clin Immunol Pract. 2019;7(3):1024–31 e3.PubMedCrossRef
61.
Jain SV, Mullins RJ. Cold urticaria: a 20-year follow-up study. J Eur Acad Dermatol Venereol. 2016;30(12):2066–71.PubMedCrossRef
62.
Katsarou-Katsari A, Makris M, Lagogianni E, Gregoriou S, Theoharides T, Kalogeromitros D. Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study. J Eur Acad Dermatol Venereol. 2008;22(12):1405–11.PubMedCrossRef
63.
Neittaanmäki H. Cold urticaria. Clinical findings in 220 patients. J Am Acad Dermatol. 1985;13(4):636–44.PubMedCrossRef
64.
Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1119–30.PubMedCrossRef
65.
•• Greenhawt M, Shaker M, Wang J, Oppenheimer JJ, Sicherer S, Keet C, et al. Peanut allergy diagnosis- a 2020 practice parameter update, systematic review, and GRADE analysis. J Allergy Clin Immunol. 2020;15:S0091-6749(20)31137-4 Thorough review of peanut allergy diagnostic testing and best approach to using each test as well as proper interpretation.
66.
Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, et al. Food allergy: a practice parameter update-2014. J Allergy Clin Immunol. 2014;134(5):1016–25.e43.PubMedCrossRef
67.
Fitzhugh DJ, Bernstein DI. Should epinephrine autoinjectors be prescribed to all patients on subcutaneous immunotherapy? J Allergy Clin Immunol Pract. 2016;4(5):862–7.PubMedCrossRef
68.
Sun D, Cafone J, Shaker M, Greenhawt M. The cost-effectiveness of requiring universal vs contextual self-injectable epinephrine autoinjector for allergen immunotherapy. Ann Allergy Asthma Immunol. 2019;123(6):582–9.PubMedCrossRef
69.
Wang Y, McKee M, Torbica A, Stuckler D. Systematic literature review on the spread of health-related misinformation on social media. Soc Sci Med. 2019;240:112552.PubMedPubMedCentralCrossRef
70.
Blaiss MS, Steven GC, Bender B, Bukstein DA, Meltzer EO, Winders T. Shared decision making for the allergist. Ann Allergy Asthma Immunol. 2019;122(5):463–70.PubMedCrossRef
71.
Tonelli MR, Sullivan MD. Person-centred shared decision making. J Eval Clin Pract. 2019;25(6):1057–62.PubMedCrossRef
72.
Greenhawt M, Shaker M, Winders T, Bukstein DA, Davis RS, Oppenheimer J, et al. Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies. Ann Allergy Asthma Immunol. 2020;125(1):90–6.PubMedCrossRef
73.
Anagnostou A, Hourihane JO, Greenhawt M. The role of shared decision making in pediatric food allergy management. J Allergy Clin Immunol Pract. 2020;8(1):46–51.PubMedCrossRef
Metadaten
Titel
Fatal Anaphylaxis: Epidemiology and Risk Factors
verfasst von
Irene Mikhail
David R. Stukus
Benjamin T. Prince
Publikationsdatum
01.04.2021
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 4/2021
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-021-01006-x

Weitere Artikel der Ausgabe 4/2021

Current Allergy and Asthma Reports 4/2021 Zur Ausgabe

Rhinosinusitis (J Mullol, Section Editor)

Herbal Medicines for Allergic Rhinitis: a Systematic Review and Meta-analysis

Rhinosinusitis (J Mullol, Section Editor)

Multidisciplinary Care for Severe or Uncontrolled Chronic Upper Airway Diseases

Immunotherapy and Immunomodulators (B Vickery, Section Editor)

How to Incorporate Oral Immunotherapy into Your Clinical Practice

Occupational Allergies (JA Poole, Section Editor)

What Is New in Occupational Allergic Contact Dermatitis in the Year of the COVID Pandemic?

Occupational Allergies (JA Poole, Section Editor)

Nutritional Factors in Occupational Lung Disease

Rhinosinusitis (J Mullol, Section Editor)

The COVID-19 Pandemic—an Epidemiological Perspective

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise